U.S. Intravenous Immunoglobulin Market Investment Trends: What to Watch in 2024

The U.S. intravenous immunoglobulin market size is expected to reach USD 10.42 billion by 2030, according to a new report by Grand View Research, Inc. It is estimated to register a CAGR of 7.7% during the forecast period, driven by the rising prevalence of primary and acquired immunodeficiency diseases such as congenital AIDS, and increased adoption of IVIG therapy. There are over 350 chronic disorders that are categorized as PIDD, and medical therapies are available for over 50% of these conditions. In addition, drugs for the treatment of the diseases are covered under Medicare Part B and reimbursement is available for home settings as well as physicians' offices, which is anticipated to drive treatment adoption.

The unmet need is high in patients, which provides immense growth opportunities for players. For instance, the treatment cost for IVIG is high, making it hard for patients to afford it without insurance or Medicare coverage. Thus, the entry of novel low-cost IVIG treatment can lead to a paradigm shift. Moreover, as per the National Institutes of Health, in 2020, over 500,000 cases of  PIDD went undiagnosed, which demonstrates the high unmet need for pharmaceuticals; if diagnosed, Immunoglobulin (Ig) replacement therapy is the standard treatment for PIDD. Regulatory and reimbursement support is acting as key drivers. For instance, as per 2021 Medicare updates, Medicare B will cover Hizentra therapy for CIDP patients as maintenance therapy. This is expected to improve access to the treatment in insured patients, as the treatment is expensive. Furthermore, in February 2021, Panzyga by Pfizer received approval for supplemental BLA. The entry of new products into the market is anticipated to act as a crucial driver in the coming years.

Gather more insights about the market drivers, restrains and growth of the U.S. Intravenous Immunoglobulin Market

Leading participants in the U.S. IVIG market are developing a variety of projects and biological products based on their patented technology. In July 2021, Octagam 10% was approved by the FDA for the treatment of dermatomyositis in adults. The launch of Octagam 10% is anticipated to have a significant impact on patients with dermatomyositis, improving the armamentarium of available treatments. Moreover, in November 2022, Biotest AG received FDA approval for Yimmugo, a next-generation IVIG. The U.S. IVIG market is oligopolistic in nature with companies such as Grifols, S.A.; CSL Behring; and Octapharma AG, holding a major share. Other small-scale players are investing in clinical trials and R&D for the production of novel IVIG products in an attempt to gain market share. Moreover, increasing attempts by major players to expand their presence with approvals for new indications for existing products is further expected to increase competitive rivalry in the market.

U.S. Intravenous Immunoglobulin Market Report Highlights

  • In 2022, primary immunodeficiency diseases held the largest share of the U.S. IVIG market attributable to long-term therapy requirements and expensive treatments
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is projected to grow at the fastest rate attributable to the increasing prevalence of the condition and coverage of drugs under medicare
  • Hospital pharmacy held the largest share of the U.S. IVIG market in 2022 owing to a large number of hospital pharmacies and easy availability of products in the hospitals
  • Key players in the U.S. IVIG market include companies such as Octapharma AG; LFB Biotechnologies; Grifols, S.A.; and CSL Behring

Browse through Grand View Research's Pharmaceuticals Industry Research Reports.

  • Scleroderma Therapeutics Market: The global scleroderma therapeutics market was valued at USD 2.53 billion in 2024 and is projected to grow at a CAGR of 5.0% from 2025 to 2030.
  • Allergy Immunotherapy Market: The global allergy immunotherapy market size was estimated at USD 1.92 billion in 2024 and is forecasted to grow at a CAGR of 8.7% from 2025 to 2030.

U.S. Intravenous Immunoglobulin Market Segmentation

Grand View Research has segmented the U.S. intravenous immunoglobulin market on the basis of application and distribution channel:

U.S. Intravenous Immunoglobulin Application Outlook (Revenue, USD Million, 2018 - 2030)

  • Primary Immunodeficiency
  • Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
  • Primary Immunodeficiency Diseases (PIDD)
  • Congenital AIDS
  • Chronic Lymphocytic Leukemia
  • Myasthenia Gravis
  • Multifocal Motor Neuropathy
  • Immune Thrombocytopenia (ITP)
  • Kawasaki Disease
  • Guillain-Barre Syndrome
  • Others

U.S. Intravenous Immunoglobulin Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

  • Hospital Pharmacy
  • Specialty Pharmacy
  • Others

Order a free sample PDF of the U.S. Intravenous Immunoglobulin Market Intelligence Study, published by Grand View Research.

Comments

Post a Comment

Popular posts from this blog

Drug Addiction - Pipeline Review, H1 2017 Market Overview and trends research report

Radiant insights, inc latest Pharmaceutical and Healthcare disease pipeline guide Drug Addiction - Pipeline Review, H1 2017, provides an overview of the Drug Addiction (Central Nervous System) pipeline landscape. Drug addiction, also called substance dependence or chemical dependency, is a disease that is characterized by a destructive pattern of drug abuse that leads to significant problems involving tolerance to or withdrawal from the substance. Drug addiction symptoms or behaviors include recurrent drug use that results in a lack of meeting important obligations at work, school, or home, inability to sleep, awake at unusual times, unusual laziness, loss of or increased in appetite, changes in eating habits, cold, sweaty palms; shaking hands., red, watery eyes; pupils larger or smaller than usual and unusual smells on breath, body or clothes. Report Highlights Radiant insights, inc Pharmaceutical and Healthcare latest pipeline guide Drug Addiction - Pipeline Review, H1 2017, p...
Read more

All Countries Dialyzer Industry 2013-2028 - Market Size, Share, Outlook, Growth, Key Players and Forecast

The global Dialyzer market was valued at $XX million in 2018, and Radiant Insights, Inc analysts predict the global market size will reach $XX million by the end of 2028, growing at a CAGR of XX% between 2018 and 2028. This report provides detailed historical analysis of global market for Dialyzer from 2013-2018, and provides extensive market forecasts from 2019-2028 by region/country and subsectors. It covers the sales volume, price, revenue, gross margin, historical growth and future perspectives in the Dialyzer market. Download Free Sample Report @ https://www.radiantinsights.com/research/2013-2028-report-on-global-dialyzer-market/request-sample Leading players of Dialyzer including: • Fresenius Medical Care • Baxter • Nipro • Asahi Kasei • Toray • B.Braun • Nikkiso • Medtronic • Kawasumi • Medica • Wego • Lengthen • Peony Medical • Chengdu OCI • Bain Medical Equipment Market split by Type, can be divided into: • Flat Type Dialyzer • Coil Tube Dialyzer • Ho...
Read more

Insights into the Medical Waste Disposal Category: A Comprehensive Procurement Intelligence Report

  Medical Waste Disposal Category Overview The medical waste disposal category is anticipated to grow at a CAGR of 6.0% from 2023 to 2030. Appropriate disposal of medical trash is the key challenge for healthcare providers across the globe. Rising awareness about the benefits of proper medical waste management for treatment, recycling, and disposal of medical trash has boosted the growth of the category. According to the World Health Organization Study Report 2022, countries with low income generate over 0.2 kg of medical trash per day per hospital bed, whereas countries with high income generate hazardous waste of up to 0.5 kg per hospital bed each day. Moreover, rising government initiatives and strict rules and regulations for waste management are also expected to drive the category. For instance, in December 2022, an MOU was signed between the Center for Health Environment Research and Development and Can Tho Central General Hospital under USAID’s Reducing Pollution Project. T...
Read more